NASDAQ:VLON Vallon Pharmaceuticals (VLON) Stock Price, News & Analysis → This Weight Loss Company Can't Make Enough Product (From Behind the Markets) (Ad) Free VLON Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.21▼$0.2550-Day Range$0.27▼$2.8752-Week Range$0.21▼$12.92Volume1.85 million shsAverage Volume5.78 million shsMarket Capitalization$2.97 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsTrendsStock AnalysisCompetitorsTrends Get Vallon Pharmaceuticals alerts: Email Address Ad Prosper Trading Academywhy 99.94% won’t make you moneyI believe there's only 5-7 stocks that you should trade in 2024. But here's the catch…because there's always a catch in life. You NEED to use a specific system when you trade them.Click here to download my options trading cheat sheet (5-7 stocks inside here) About Vallon Pharmaceuticals Stock (NASDAQ:VLON)Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.Read More Ad Prosper Trading Academywhy 99.94% won’t make you moneyI believe there's only 5-7 stocks that you should trade in 2024. But here's the catch…because there's always a catch in life. You NEED to use a specific system when you trade them.Click here to download my options trading cheat sheet (5-7 stocks inside here) VLON Stock News HeadlinesJuly 21, 2023 | forbes.comQuestcor Pharmaceuticals,April 20, 2023 | bizjournals.comVallon Pharmaceuticals' shareholders approve reverse merger with California companyApril 20, 2023 | finance.yahoo.comVallon Pharmaceuticals Announces Stockholder Approval of Merger with GRI Bio, Inc. and Reverse Stock SplitApril 12, 2023 | finance.yahoo.comVallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023April 7, 2023 | bizjournals.comLab Notes: CHOP gets $10M research gift; Vallon seeks greater shareholder support for mergerApril 4, 2023 | finance.yahoo.comVallon Pharmaceuticals Provides an Update on Proxy Voting for the Proposed Merger with GRI Bio and Urges Stockholders of Record as of March 6, 2023 to Vote by April 11, 2023, at 11:59 PM ETFebruary 24, 2023 | finanznachrichten.deVallon Pharmaceuticals Inc.: Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial ResultsFebruary 24, 2023 | finance.yahoo.comVallon Pharmaceuticals Reports Fiscal Year 2022 Financial ResultsFebruary 14, 2023 | benzinga.comIs Vallon Pharmaceuticals Inc (VLON) recent surge justifiedJanuary 11, 2023 | finance.yahoo.comVallon Pharmaceuticals and GRI Bio to Present at the Virtual Investor 2023 Companies to Watch EventDecember 27, 2022 | benzinga.comSHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Vallon Pharmaceuticals, Inc. - VLONDecember 14, 2022 | bizjournals.comVallon Pharmaceuticals to merge with California biotech firm in 'best path forward'December 14, 2022 | msn.comWhat's Going On With Vallon Pharmaceuticals Stock Today?December 14, 2022 | benzinga.comWhy Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving PremarketDecember 13, 2022 | finance.yahoo.comVallon Pharmaceuticals and GRI Bio Enter into Merger Agreement with Goal of Advancing Innovative Pipeline of NKT Cell RegulatorsNovember 3, 2022 | finance.yahoo.comVallon Pharmaceuticals Reports Third Quarter 2022 Financial ResultsJuly 28, 2022 | finance.yahoo.comVallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateJuly 20, 2022 | finance.yahoo.comVallon Pharmaceuticals, Inc. (VLON)May 16, 2022 | bizjournals.comVallon Pharmaceuticals plans $3.9M stock sale to support exploration of strategic alternativesMay 13, 2022 | seekingalpha.comVallon Pharmaceuticals to raise $3.9M in stock offeringMay 13, 2022 | finance.yahoo.comVallon Pharmaceuticals Announces $3.9 Million Registered Direct OfferingMay 12, 2022 | finance.yahoo.comVallon Pharma Posts Additional Data From SEAL Study Of Formulated CNS StimulantMay 12, 2022 | finance.yahoo.comVallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIRMay 11, 2022 | finance.yahoo.comVallon Pharmaceuticals Announces Issuance of Japanese Patent Covering Composition of Matter and Methods of Manufacturing for ADAIRMay 9, 2022 | finance.yahoo.comVallon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate UpdateSee More Headlines Receive VLON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vallon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VLON CUSIPN/A CIK1824293 Webwww.vallon-pharma.com Phone267-607-8255FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,020,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-230.48% Return on Assets-124.89% Debt Debt-to-Equity RatioN/A Current Ratio2.29 Quick Ratio2.29 Sales & Book Value Annual Sales$100,000.00 Price / Sales29.67 Cash FlowN/A Price / Cash FlowN/A Book Value$0.18 per share Price / Book1.22Miscellaneous Outstanding Shares13,482,000Free Float8,453,000Market Cap$2.97 million OptionableNot Optionable Beta-1.14 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. David C. Baker (Age 59)CEO, Pres & Director Comp: $553.55kMs. Leanne M. Kelly (Age 45)Chief Financial Officer Comp: $328.52kDr. Ofir Levi Ph.D. (Age 48)Consulting Dr. Timothy M. Whitaker (Age 63)Chief Medical Officer Key CompetitorsCan-Fite BioPharmaNYSE:CANFRedHill BiopharmaNASDAQ:RDHLAvalo TherapeuticsNASDAQ:AVTXElevai LabsNASDAQ:ELABMIRA PharmaceuticalsNASDAQ:MIRAView All Competitors VLON Stock Analysis - Frequently Asked Questions When did Vallon Pharmaceuticals' stock split? Vallon Pharmaceuticals shares reverse split on the morning of Monday, April 24th 2023. The 1-30 reverse split was announced on Monday, April 24th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Vallon Pharmaceuticals IPO? Vallon Pharmaceuticals (VLON) raised $15 million in an initial public offering on Wednesday, February 10th 2021. The company issued 1,700,000 shares at $8.00-$10.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO. This page (NASDAQ:VLON) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vallon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vallon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.